Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Pediatr Endocrinol Metab ; 19 Suppl 2: 607-17, 2006 May.
Article in English | MEDLINE | ID: mdl-16789624

ABSTRACT

Gonadal hyperfunction is the most frequent endocrine dysfunction in females with McCune-Albright syndrome (MAS). Peripheral precocious puberty is usually the first MAS manifestation in children, characterized by episodes of hypersecretion of estrogens with a consequent reduction in gonadotropin secretion. Little is known about the course of this endocrine disease in adolescence and during young adult life. The aim of this study was to evaluate ovarian function in 10 females with MAS (age 11.4-20.1 years) to detect the persistence of autonomous ovarian hyperfunction throughout and following adolescence, after at least 1 year wash out of any treatment for precocious puberty. LH, FSH, estradiol, prolactin, androgen secretion, ovarian and breast sonography in luteal and follicular phases of some menstrual cycles were evaluated. We demonstrated the persistence of some ovarian autonomy, documented by hyperestrogenism and/or low or absent gonadotropin secretion and/or ovarian cysts.


Subject(s)
Estrogens/metabolism , Fibrous Dysplasia, Polyostotic/complications , Ovarian Cysts/complications , Ovary/physiopathology , Puberty, Precocious/physiopathology , Adolescent , Adult , Age Determination by Skeleton , Child , Child, Preschool , Female , Fibrous Dysplasia, Polyostotic/diagnosis , Fibrous Dysplasia, Polyostotic/physiopathology , Follow-Up Studies , Gonadotropins/physiology , Humans , Menstrual Cycle , Ovarian Cysts/diagnostic imaging , Ovarian Cysts/physiopathology , Ovarian Diseases/etiology , Ovarian Diseases/metabolism , Ovary/diagnostic imaging , Puberty, Precocious/complications , Puberty, Precocious/diagnosis , Puberty, Precocious/drug therapy , Steroids/therapeutic use , Treatment Outcome , Ultrasonography
2.
J Pediatr Hematol Oncol ; 27(3): 141-4, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15750445

ABSTRACT

Children with acute lymphoblastic leukemia (ALL) receive as part of induction therapy a 4-week course of high-dose glucocorticoid, which is either abruptly discontinued or shortly tapered. The aim of this study was to evaluate the signs and symptoms of steroid withdrawal syndrome and performance status (according to Lansky scale) during the 9-day tapering period and 1 week after withdrawal of the steroid in 63 children randomly allocated to receive prednisone or dexamethasone as part of induction treatment according the AIEOP ALL 2000 protocol. Twenty of 28 (75%) patients on dexamethasone versus 18 of 35 (51.4%) on prednisone (P < 0.05) developed at least one steroid withdrawal symptom during the study period. Three or more symptoms were observed in 39.3% (11/28) of the dexamethasone group and 8.6% (3/35) of the prednisone group (P < 0.05). Dexamethasone patients developed clinical signs earlier (within 3 days from the steroid tapering) than symptomatic prednisone patients. In the prednisone group, the symptoms were less severe and the performance status was higher (P < 0.05). Steroid withdrawal morbidity in ALL children during induction is a frequent and clinically relevant complaint. A more gradual (for dexamethasone) or a more prolonged (for prednisone) tapering might be suggested.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Dexamethasone/adverse effects , Glucocorticoids/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Prednisone/adverse effects , Substance Withdrawal Syndrome/epidemiology , Adolescent , Child , Child, Preschool , Dexamethasone/therapeutic use , Female , Glucocorticoids/therapeutic use , Humans , Infant , Male , Prednisone/therapeutic use , Substance Withdrawal Syndrome/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL